GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pulmonx Corp (NAS:LUNG) » Definitions » EPS without NRI
中文

Pulmonx (Pulmonx) EPS without NRI

: $-1.60 (TTM As of Dec. 2023)
View and export this data going back to 2020. Start your Free Trial

Pulmonx's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $-0.36. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.60.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 20.30% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -10.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Pulmonx's EPS without NRI or its related term are showing as below:

LUNG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -16.7   Med: -14.8   Max: 20.3
Current: 20.3

During the past 6 years, Pulmonx's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 20.30% per year. The lowest was -16.70% per year. And the median was -14.80% per year.

LUNG's 3-Year EPS without NRI Growth Rate is ranked better than
62.82% of 702 companies
in the Medical Devices & Instruments industry
Industry Median: 9.7 vs LUNG: 20.30

Pulmonx's EPS (Diluted) for the three months ended in Dec. 2023 was $-0.36. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.60.

Pulmonx's EPS (Basic) for the three months ended in Dec. 2023 was $-0.36. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.60.


Pulmonx EPS without NRI Historical Data

The historical data trend for Pulmonx's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulmonx Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial -1.00 -3.16 -1.35 -1.59 -1.60

Pulmonx Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.38 -0.42 -0.43 -0.39 -0.36

Competitive Comparison

For the Medical Devices subindustry, Pulmonx's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pulmonx PE Ratio without NRI Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Pulmonx's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Pulmonx's PE Ratio without NRI falls into.



Pulmonx EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pulmonx  (NAS:LUNG) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Pulmonx EPS without NRI Related Terms

Thank you for viewing the detailed overview of Pulmonx's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Pulmonx (Pulmonx) Business Description

Traded in Other Exchanges
Address
700 Chesapeake Drive, Redwood, CA, USA, 94063
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). the company's solutions comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the U.S. and international markets.
Executives
French Glendon E. Iii director, officer: President and CEO 700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Geoffrey Beran Rose officer: Chief Commercial Officer 5124 ROCKWOOD PARKWAY NW, WASHINGTON DC 20016
John Mckune officer: Interim CFO 46668 CRAWFORD CT., FREMONT CA 94539
David Aaron Lehman officer: General Counsel C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Derrick Sung officer: Chief Financial Officer C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 380, SAN FRANCISCO CA 94103
Alissa Hsu Lynch director 700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Richard M Ferrari director 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Tiffany Sullivan director 700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Boston Scientific Corp 10 percent owner 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Daniel P Florin director 56 E. BELL DRIVE, WARSAW IN 46581
Mead Dana G Jr. director 2750 SAND HILL ROAD, MENLO PARK CA 94025
Thomas William Burns director C/O GLAUKOS CORPORATION,, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Georgia Melenikiotou director C/O INSPIRE MEDICAL SYSTEMS, INC., 5500 WAYZATA BOULEVARD, SUITE 1600, GOLDEN VALLEY MN 55416
Staffan Lindstrand director C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51